Loading clinical trials...
Loading clinical trials...
Oral Deucrictibant for the Prophylactic and Acute Treatment in Patients With Bradykinin Mediated Angioedema With Normal C1 Inhibitor (BK-AE-nC1INH)
Conditions
Interventions
Deucrictibant XR tablet
Placebo comparator to XR tablet
+2 more
Locations
1
United States
Institute For Asthma & Allergy
Wheaton, Maryland, United States
Start Date
March 10, 2025
Primary Completion Date
April 1, 2026
Completion Date
April 1, 2026
Last Updated
July 2, 2025
NCT06960213
NCT07001280
NCT07298447
NCT06842823
NCT06573723
NCT05396105
Lead Sponsor
Institute for Asthma and Allergy
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions